FLOVENT HFA
ICS MDI
Fluticasone propionate · GlaxoSmithKline
Discontinued by manufacturer
GSK discontinued branded Flovent in the US effective January 1, 2024. An identical authorized generic (fluticasone propionate inhalation aerosol, distributed by Prasco) remains available. A first ANDA generic (Glenmark, 44 mcg strength only) launched in March 2026.
GSK position on FloventActive Medication & Mechanism
- Fluticasone propionate ICS44 mcg, 110 mcg, or 220 mcg per actuation
Synthetic corticosteroid with potent anti-inflammatory activity. Reduces airway inflammation by suppressing inflammatory cell recruitment and cytokine production.
FDA-Approved Dosing — Strength × Indication
Strength Regimen Asthma
44 mcg
2 inhalations twice daily (~12 hours apart) → 176 mcg
FDA Approved
Starting dose for patients previously on bronchodilators alone.
110 mcg
2 inhalations twice daily → 440 mcg
FDA Approved
For patients previously on ICS. Recommended starting dose for adults.
220 mcg
2 inhalations twice daily → 880 mcg
FDA Approved
Maximum dose for patients previously on oral corticosteroids.
All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling
44 mcg 2 inhalations twice daily (~12 hours apart) → 176 mcg
Asthma FDA Approved
Starting dose for patients previously on bronchodilators alone.
110 mcg 2 inhalations twice daily → 440 mcg
Asthma FDA Approved
For patients previously on ICS. Recommended starting dose for adults.
220 mcg 2 inhalations twice daily → 880 mcg
Asthma FDA Approved
Maximum dose for patients previously on oral corticosteroids.
All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling
Not a rescue inhaler. Not for acute relief. Use a SABA.
Related Inhalers
Same active ingredients (Fluticasone)